Project Grant R01DA060753

Award Date 7/1/24
Completion Date 4/30/29
Dollars Obligated $1.5M
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Omaha, NE 68198, USA
Similar Awards
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $804,728 to the Regents of the University of California at Riverside to investigate the role of methamphetamine and cysteinyl leukotrienes in HIV persistence. The research aims to: 1) Determine how methamphetamine engages the cysteinyl leukotriene-cysteinyl leukotriene receptor 1 (CYSLT-CYSLTR1) axis to increase HIV infection of CD4+ T-cells and...
The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), has awarded a $1,372,480 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Board of Regents of the University of Nebraska's University of Nebraska Medical Center (UNMC) division. The 5-year grant, effective April 15, 2025 through January 31, 2030, will fund research to elucidate the molecular mechanisms by which the interplay of HIV transactivator of transcription...
This Project Grant award, totaling $1,481,760 and provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to investigate how methamphetamine (MA) use promotes immune dysfunction in people living with HIV (PWH) even during antiretroviral therapy (ART) suppression. The research aims to determine how MA-induced activation of the NLRP3 inflammasome leads to altered metabolism, epigenetics, and immune dysfunction in T...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), will support research to spatially characterize HIV-host cellular interactions in the central nervous system (CNS) of people with HIV (PWH) who died suddenly. The $983,672 award will fund the development and implementation of innovative single-cell and spatial genomic assays to analyze the localization, distribution, and activity of HIV-infected...
This federal Project Grant award for $263,119 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) is focused on developing NLRP3 inhibitors to address HIV-associated neuroinflammation in cocaine use. The key objectives are to computationally design, synthesize, and screen novel analogues of a lead compound, AMS-17, to improve its biological activity and maintain low toxicity. The project involves in vitro and in vivo screening of...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), will support research focused on understanding the role of HIV proteins in psychostimulant abuse. The $1,465,275 grant, awarded on May 1, 2025, will enable researchers at the University of Alabama at Birmingham (UAB) to investigate how the HIV Trans-Activator of Transcription (Tat) protein modulates the effects of amphetamine on dopamine...
The National Institute on Drug Abuse (NIDA) awarded a $2,223,769 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of California, San Diego (UCSD) to investigate the individual and combined impact of HIV and opioids on inflammasome-mediated neuroinflammation and neurotoxicity. The 5-year study, which commenced on April 15, 2025, aims to uncover the mechanistic intersection between HIV and opioids that leads to more severe neurological...
This Project Grant award of $1,742,971.00 was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate the role of cannabinoids in modulating inflammasome activation and gut-brain axis dysregulation induced by cocaine use in chronic HIV/SIV infection. The primary objectives are to: 1) Investigate epigenetic mechanisms underlying cannabinoid-mediated reduction of cocaine-induced inflammasome activation in blood, brain,...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $234,000 to Georgetown University to conduct research on the effect of opioids on HIV transcription and latency. The key objectives are to understand the mechanisms by which opioids like fentanyl, morphine, and methadone influence HIV proviral transcription in microglia and astrocytes, and to use a novel dual fluorescent and bioluminescent virus to...
The National Institutes of Health (NIH), through the Mental Health Research Grants program (CFDA 93.242) administered by the National Institute of Mental Health (NIMH), has awarded a $434,500 R21 grant to the University of California, San Diego (UCSD) to investigate the epigenetic mechanisms controlling HIV latency and neuropathogenesis in microglia. The project aims to use single-cell multi-omics approaches and state-of-the-art sequencing technologies to characterize the transcriptomic and...

EPIGENETIC REGULATION OF ASTROCYTE-SPECIFIC NLRP6 INFLAMMASOME AND PANOPTOSIS IN HIV TAT AND METHAMPHETAMINE-MEDIATED NEUROINFLAMMATION - PROJECT SUMMARY: ACCORDING TO THE CENTERS FOR DISEASE CONTROL AND PREVENTION, HIV INFECTION AND DRUG ABUSE ARE INTERTWINED EPIDEMICS THAT LIMIT ADHERENCE TO COMBINATION ANTIRETROVIRAL THERAPY (CART) AND CONTRIBUTE TO THE WORSENING OF HIV-ASSOCIATED NEUROCOGNITIVE DISORDERS REFERRED TO AS "NEUROHIV." DESPITE THE ABILITY OF CART TO SIGNIFICANTLY DECREASE VIREMIA, THE BRAIN REMAINS A RESERVOIR OF LOW-LEVEL HIV REPLICATION WITH THE ACCUMULATION AND PERSISTENCE OF CYTOTOXIC VIRAL PROTEINS, INCLUDING THE HIV TRANSACTIVATOR OF TRANSCRIPTION (TAT). METHAMPHETAMINE IS A HIGHLY ADDICTIVE SYNTHETIC STIMULANT COMMONLY ABUSED BY HIV-INFECTED PEOPLE WORLDWIDE. IT IS GENERALLY ESTABLISHED THAT HIV/HIV PROTEINS AND METHAMPHETAMINE ACTIVATE INFLAMMASOMES IN CENTRAL NERVOUS SYSTEM CELLS, PARTICULARLY MICROGLIA. HOWEVER, THERE IS A KNOWLEDGE GAP IN OUR UNDERSTANDING OF HOW HIV/HIV PROTEINS AND METHAMPHETAMINE CONTRIBUTE TO ACTIVATING ASTROCYTE-SPECIFIC INFLAMMASOMES - NLRP6, LEADING TO NEUROINFLAMMATION, WHICH IS THE FOCUS OF THIS STUDY. THE LONG-TERM GOAL IS TO IDENTIFY THE MOLECULAR MECHANISM(S) INVOLVED IN HIV AND METHAMPHETAMINE-MEDIATED ASTROCYTE ACTIVATION, WHICH CAN SET THE STAGE FOR DEVELOPING NOVEL THERAPEUTIC TARGETS TO ALLEVIATE NEUROINFLAMMATION ASSOCIATED WITH NEUROHIV. THIS PROPOSAL USES IN VITRO, EX VIVO, AND IN VIVO APPROACHES TO IDENTIFY THE MOLECULAR MECHANISM(S) INVOLVED IN HIV TAT AND METHAMPHETAMINE-MEDIATED ASTROCYTE-SPECIFIC NLRP6 INFLAMMASOME AND ITS ROLE IN PANOPTOSIS-MEDIATED NEUROINFLAMMATION. THE CENTRAL HYPOTHESIS IS THAT HIV TAT-MEDIATED ASTROCYTE ACTIVATION AND NEUROINFLAMMATION IN NEUROHIV INVOLVE ZBP1/NLRP6-MEDIATED PANOPTOSIS. THE HYPOTHESIS WILL BE TESTED WITH TWO SPECIFIC AIMS, AND THE OUTCOME OF THIS STUDY WILL SET THE STAGE FOR DEVELOPING NOVEL THERAPEUTICS TO DAMPEN HIV AND DRUG ABUSE- MEDIATED NEUROINFLAMMATION IN NEUROHIV. OVERALL, THIS R01 APPLICATION AIMS TO DETERMINE HOW EXPOSURE TO HIV TAT AND METHAMPHETAMINE INDUCES THE ASTROCYTE-SPECIFIC INFLAMMASOME, NLRP6, AND ITS ROLE IN PANOPTOSIS- MEDIATED NEUROINFLAMMATION USING IN VITRO, EX VIVO, AND IN VIVO APPROACHES.

Posted 6/25/24, 12:00 AM